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Abstract: Diaries are frequently used to evaluate therapy. Forgetfulness, however, can lead to missed entries. With paper 
diaries, these missing entries can be backfilled, compromising the reasons for using a diary. Electronic diaries are a poten-
tial means of mitigating this limitation. The pilot study was conducted to evaluate use of a mobile phone diary. Twelve 
subjects with mild persistent asthma were randomly assigned to mobile or paper diary for 2 weeks and then crossed over 
to use the other diary type for next 2 weeks. Of the 12 subjects, 7 preferred the mobile diary. However, the mean preva-
lence of missing data was greater when using the mobile (18% ± 9%) compared to paper diary (9% ± 4%; P = 0.05). In 
conclusion, the mobile diary was preferred by slightly more subjects. The greater prevalence of missing data when using 
this diary most likely results from the inability to backfill missing entries. 
Trial Registration: Clintrials.gov NCT00367263 (http://clinicaltrials.gov/ct2/show/NCT00367263). 
INTRODUCTION 
  Recent guidelines recommend controller therapy in the 
management of patients with persistent asthma and state that 
an ICS is the most effective controller currently available [1, 
2]. However, whether meaningful differences exist between 
the various ICSs that have been approved for clinical use 
remains unresolved. For example, ciclesonide, delivered as a 
solution in a HFA MDI (Alvesco
®, Sanofi-Aventis U.S., 
Bridgewater, NJ; Nycomed/Altana Pharma U.S., Florham 
Park, NJ.) has been found to have superior safety and/or effi-
cacy than older ICS in some trials [3-5] but not in others [6-
8]. 
  Evaluating individual ICSs frequently requires collecting 
data from outpatients on a daily basis over a prolonged pe-
riod of time. Typically, a written patient diary is employed 
for this collection [8-11]. However, the effectiveness of this 
collection is often limited by noncompliance of study sub-
jects with the prescribed protocol for diary entries [12]. Lack 
of diligence, motivation and simple forgetfulness, however, 
can lead to missed diary entries; moreover, these missed en-
tries are not always recognized as such since embarrassment 
and/or lack of understanding promotes backfilling of these 
entries prior to returning the diary to the investigator [13]. 
Even when performed in good faith, this backfilling defeats 
the purpose of using a diary to minimize the effects of recall 
and subsequent events on outcomes [13]. 
  More recently, use of electronic diaries has been recom-
mended as a potential means of overcoming this limitation 
[13-16]. These electronic diaries can encourage real-time 
compliance through the use of interactive features, such as  
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signaling the subject when assessments are due, permitting 
responses only during particular windows of time, and time 
stamping these responses [13]. Acceptance of these elec-
tronic systems, however, can vary depending upon their en-
gineering requirements. Devices vary in their requirements 
for downloading data. Some store diary entries which are 
downloaded at the study site. Others have the subject trans-
mit their entries directly to a server via an analogue or digital 
phone line. These types of phone connections are becoming 
less prevalent with cell phones far surpassing the number of 
wired connections worldwide [17]. Therefore, a wireless 
system would be advantageous. In addition, overall ease of 
use and subject familiarity/comfort with similar electronic 
devices should enhance acceptance of these electronic sys-
tems [14]. 
 The  VOCEL
® Mobile Diary is a new mobile phone-based 
system that can capture and transmit study data. It is light-
weight, portable, and adaptable to the needs of a particular 
trial. It can remind subjects when it’s time to take study 
medication and/or enter their report and can then time stamp 
this report. Use of this dairy system in a clinical trial has not 
been previously evaluated. The objective of this pilot evalua-
tion was to assess use and patient acceptance of the VO-
CEL
® Mobile Diary in comparison with standard paper re-
porting methods in documenting the efficacy, safety, com-
pliance, and convenience of inhaled ciclesonide in patients 
with mild to moderate persistent asthma. Secondarily, we 
documented effect sizes and explored the statistical signifi-
cance of larger observed effects. 
MATERIALS AND METHODOLOGY 
  This was a single center, randomized, cross-over evalua-
tion of subjects with mild to moderate persistent asthma. 
Following a screening assessment which included medical 
history, physical examination, and pulmonary function test-
ing, subjects were issued a traditional paper (Fig. 1) or VO-Mobile Phone vs Paper Diary in Subjects with Mild to Moderate Persistent Asthma  The Open Respiratory Medicine Journal, 2008, Volume 2    73 
CEL
® Mobile Diary (Fig. 2) in random order and instructed 
to complete this diary twice daily for a period of 2 weeks. In 
addition, subjects randomized to the mobile phone diary re-
ceived an electronic alert from the device at each scheduled 
time for diary entry throughout the evaluation period. At the 
end of this period (±2 days), subjects returned their diary, 
had their pulmonary functions assessed, and were issued the 
other diary to use for the next 2 weeks. Subjects then re-
turned the second diary, had their pulmonary functions reas-
sessed, and answered questions regarding both diary type 
preference and study medication (see Appendix 1 for exact 
questions). 
  Subjects currently taking an ICS were instructed to re-
frain from using this agent for the duration of the study. All 
subjects were given a ciclesonide MDI (40 g/puff) as con-
troller therapy and instructed to take 2 puffs twice daily (to-
tal daily dose 160 g ciclesonide) throughout the study. This 
change in prescription mimics conditions likely when testing 
a new medication or a medication new to the patient. In addi-
tion, all subjects were given an albuterol MDI as rescue 
medication to be used on an as needed basis throughout the 
study. Finally, all subjects were given a PIKO-1™ (Pulmo-
nary Data Services, Inc., Louisville, CO) peak flow meter  
 
and instructed in its use. Subjects were told to measure their 
PEFR 3 consecutive times just before their morning and 
evening ciclesonide dose and to record the greatest of these 3 
measurements in their diary. 
Study Population 
  The study population consisted of male and female sub-
jects  12 years of age with mild to moderate persistent 
asthma, as defined by the National Heart, Lung, and Blood 
Institute [18], for at least 6 months. Eligible subjects in-
cluded patients who had received no ICS therapy, ICS mono-
therapy, or ICS in combination with a long acting beta ago-
nist in the 30 days prior to screening. Subjects were excluded 
from study participation if they had a respiratory tract infec-
tion in the preceding 14 days; had active or quiescent tuber-
culosis; had a history of chronic bronchitis, chronic obstruc-
tive pulmonary disease, or emphysema; smoked tobacco in 
the preceding 6 months or had a lifetime 10 pack-year smok-
ing history; had any other serious concomitant disease or 
condition that might interfere with study completion or in-
terpretation; had received an investigational drug within the 
past 30 days; were pregnant or trying to become pregnant; or 
were breast feeding. 
 
 
Fig. (1). Traditional paper diary used in the current evaluation. 74    The Open Respiratory Medicine Journal, 2008, Volume 2  Meltzer et al. 
 
 
Fig. (2). Screens (A through F) of the VOCEL
® Mobile Diary as configured for the current evaluation. Mobile Phone vs Paper Diary in Subjects with Mild to Moderate Persistent Asthma  The Open Respiratory Medicine Journal, 2008, Volume 2    75 
  The study protocol was approved by the Sterling Institu-
tional Review Board and all subjects provided written in-
formed consent prior to participation in any study specific 
procedures. 
Outcome Measures 
  The primary outcome measure was the proportion of sub-
jects who preferred using the VOCEL
® Mobile Diary vs the 
traditional paper diary. 
  Secondary outcome measures included 1) influence of 
diary type on drug assessment as reflected by recorded com-
pliance, use of rescue medication, PEFRs, asthma symptom 
scores, and nocturnal awakenings and 2) ciclesonide efficacy 
and safety as reflected by both diary entries and objective 
assessment of pulmonary function at the end of each diary 
period. 
Statistical Analysis 
  As a pilot evaluation, this study was not designed to detect 
group differences across the variables analyzed and a formal 
power analysis was not performed prior to study initiation. 
Data were inspected concerning distributional assumptions for 
the statistical tests to be employed. It is common for small 
samples to result in skewed distributions. For this study, all 
analyses were computed with both parametric and non-
parametric analyses. Parametric analyses were reported for 
ease of interpretation. Participants were not moved from one 
condition to the other based on evidence of exposure to the 
“wrong” condition. In this sense, an intent-to-treat analysis 
was employed. However, missing data were ignored and im-
putation procedures were not used. All analyses were com-
puted using standard statistical program packages (SPSS). 
  Subjects functioned as their own control with pairwise 
tests used to compare subjects after each diary period. Data 
were analyzed using descriptive statistics and general linear 
models (GLM) to test for differences between and within 
conditions with P 0.05 used to indicate statistical signifi-
cance. These parametric analyses were confirmed using the 
Wilcoxon nonparametric test. Significance is reported for 
either the Wilcoxon or the GLM test. Unless otherwise indi-
cated, data are reported as mean ± standard deviation. 
RESULTS 
Study Population 
  Thirteen potential subjects were screened. Of these, 1 
was disqualified from study participation on the basis of a 
36% FEV1 at screening. The remaining 12 subjects (Table 1) 
were subsequently randomized and completed the trial. 
Diary Preference 
  Of the 12 subjects, 7 preferred using the mobile phone 
diary and 5 the paper diary (Table 2). In addition, 8 of the 
subjects believed that the mobile diary was more accurate 
than the paper diary and 9 of the subjects believed that it 
helped them remember to take their medication. In compari-
son, 6 of the subjects believed that the paper diary helped 
them remember to take their medication. All 12 subjects be-
lieved that they provided honest and accurate reports during 
both diary conditions. 
  Eleven of the 12 subjects considered the mobile diary to 
be simple to use. The 1 subject who had difficulty using the 
mobile diary was an individual who had no prior experience 
using either a computer or a mobile phone. Despite this, 
study subjects were less likely to report all their data when 
using the mobile diary. Only 3 subjects stated that they re-
corded all their symptoms when using the mobile diary com-
pared to 9 subjects for the paper diary. Similarly, only 7 sub-
jects stated that they recorded all their PEFRs when using the 
mobile diary compared to 10 subjects for the paper diary. 
This discrepancy between perceived ease of use and actual 
use of the mobile diary appears to be related to timing issues. 
Only 7 subjects considered the mobile diary to be very quick 
to use. In addition, 2 subjects noted the inability to change 
the programmed reminder times and 2 subjects noted the 
inability to enter data late, following expiration of the pro-
grammed entry window for specific data as limitations of the 
mobile diary. 
Diary Data 
  There was an association between data reporting and the 
type of diary employed (Table 2). The prevalence of missing 
diary entries was 20% in 4 subjects when using the mobile 
diary compared to only 1 subject when using the paper diary. 
Table 1.  Baseline Demographic and Clinical Information 
 
Subject Age  (yrs)  Gender  Race  Previous Experience Using Diaries  ICS Use at Baseline  Percent FEV1 at Baseline  Initial Diary 
1 61  Male  Caucasian  Yes  Yes  59  Paper 
2 41  Female  Caucasian Yes  No  90  Paper 
3 36  Female  Caucasian No  Yes 96  Paper 
4 44  Female  African American  Yes No  93  Paper 
5 43  Female  Caucasian Yes  No  86  Paper 
6 43  Male  Caucasian  No  No  68  Mobile 
7 19  Male  Caucasian  Yes  No  84  Mobile 
8 21  Male  Caucasian  Yes  No  116  Paper 
9 45  Male  African  American  Yes Yes  75  Mobile 
10 23  Female  African American  Yes No  90  Mobile 
11 42  Female  Caucasian Yes  No  87  Mobile 
12 16  Male  African  American  Yes No  91  Mobile 76    The Open Respiratory Medicine Journal, 2008, Volume 2  Meltzer et al. 
As a result, the mean prevalence of missing data points was 
significantly greater when using the mobile (18% ± 9%) 
compared to paper diary (9% ± 4%; P = 0.05). In addition, 
reported compliance with the treatment regimen was 8.6% 
lower (Mobile: 24.50 ± 2.75 mean total doses; Paper: 26.92 
± 1.83 mean total doses; P = 0.05). Each of these was sig-
nificant in both Wilcoxon and the GLM analyses. 
  The following measures were significantly different in 
either Wilcoxon or GLM analyses but not both and thus 
should be considered as trends to be confirmed by future 
study. Reported use of rescue medication was 40% lower 
when using the mobile (4.42 ± 5.50 doses) compared to pa-
per (7.33 ± 6.84 doses; P = 0.03 [GLM]) diary. In addition, 
there were more missing PEFRs (Mobile: 5.25 ± 2.38; Paper: 
2.92 ± 0.24; P = 0.01 [GLM]) and mean total symptom score 
was lower (Mobile: 0.50 ± 0.39; Paper: 0.94 ± 0.78; P = 0.03 
[Wilcoxon]) when using the mobile diary. 
  Reported PEFRs (Mobile: 439.77 ± 89.81 L/min; Paper: 
438.69 ± 90.37 L/min), mean daytime symptom score (Mo-
bile: 0.21 ± 0.17; Paper: 0.28 ± 0.29), mean nighttime symp-
tom score (Mobile: 0.36 ± 0.35; Paper: 1.57 ± 0.51), and 
total number of nighttime awakenings due to asthma (Mo-
bile: 0.25 ± 0.62; Paper: 0.42 ± 0.90) were not significantly 
different between diary types when tested by either Wil-
coxon or GLM analyses. 
Pulmonary Function Data 
  Spirometry performed at the end of each treatment period 
suggests that, if anything, pulmonary functions were better 
when the subjects used the mobile diary. Overall, FEV1 (Fig. 
3) and FEV1% (Table 2) improved 1% of predicted normal 
in 7 out of the 12 (58%) subjects during the mobile diary 
period compared to only 3 subjects (25%) during the paper 
diary period. These differences did not reach significance by 
either test but power (17%) was not sufficient to test the sig-
nificance of differences as small as those observed in this 
sample. 
 
Fig. (3). Prevalence of baseline change in FEV1 over each 2 week 
treatment period by diary type. 
Ciclesonide Safety and Ease of Use 
  Headache/sinus pain (3 subjects), chest pain/discomfort 
(2 subjects), and diarrhea (2 subjects) were the most com-
monly reported adverse events. No serious adverse events 
were reported and no subject discontinued the study because 
of an adverse event. 
  All 12 subjects considered the ciclesonide MDI to be 
very simple to learn how to use and 10 of the subjects stated 
that they experienced no trouble using the inhaler during the 
study period. 
DISCUSSION 
  In this evaluation, there was a slight preference for use of 
the mobile phone diary. In addition, most subjects thought 
that the mobile diary was simple to use, potentially more 
accurate than the paper diary, and helpful in reminding them 
to take their medication. However, given the sample size, 
these findings cannot be considered definitive but instead 
should be used to generate questions and hypotheses for fu-
ture larger scale and more completely controlled trials. 
  Since 9 of the 12 subjects stated that the mobile diary 
was helpful in reminding them to take their medication, one 
would expect greater treatment compliance when subjects 
were using the mobile dairy. It is surprising then, that the 
treatment compliance reported when using the mobile diary 
was actually 8.6% lower than that reported when using the 
paper diary. Given the reported symptom scores, use of res-
cue medication, nighttime awakenings, PEFRs, and meas-
ured FEV1s this may not reflect lower adherence to the dos-
ing regimen during the mobile diary phase but instead might 
represents erroneous reporting of compliance when using the 
paper diary by indicating that medication was taken when, in 
fact, it was taken out of schedule or not taken at all. 
  Reported use of rescue medication was 40% lower when 
using the mobile compared to paper diary. However, this 
finding was statistically significant in only one of the two 
analyses and further investigation is warranted to confirm the 
significance of this finding. If confirmed, it would be impor-
tant to determine whether, similar to treatment compliance, 
this difference reflects erroneous reporting of rescue medica-
tion use or a true benefit of the mobile diary, caused by 
greater patient attention to their clinical status and regular 
use of controller medication engendered by the twice daily 
reminders. 
  Although this study was not designed to assess the accu-
racy of data collection using either diary type, there are sug-
gestions that discrepancies in reported data between the 2 
diary types are due to limitations of one or both diary types. 
Subjects stated that the inability to enter data after expiration 
of the predefined entry window for that data was a limitation 
of the mobile diary. However, after discussion with study 
staff, they came to recognize that the mobile diary is de-
signed to prevent this type of data entry and the reason for 
this restriction. This restriction probably accounts for the 
higher prevalence of missing data when using the mobile 
diary. Several evaluations comparing electronic diaries that 
prevent out-of-window responses with traditional paper dia-
ries have demonstrated similar lower completion rates for the 
electronic diaries [16, 19-21]. However, this reduction in 
completion rate may actually result in a more accurate reflec-
tion of the true data. One of the main advantages of diaries 
compared to recall questionnaires is obtaining responses at 
or near the time of the event in question, minimize the con-
founding effects of subject recall and subsequent events on 
these responses [13]. Diary responses that are not entered Mobile Phone vs Paper Diary in Subjects with Mild to Moderate Persistent Asthma  The Open Respiratory Medicine Journal, 2008, Volume 2    77 
contemporaneous with the event in question are subject to 
these same confounding effects, eliminating this advantage. 
Entries in paper diaries are not time stamped and are fre-
quently not made at the time the investigator expects, poten-
tially introducing errors into the analysis. In one study, for 
example, subjects were asked to record data in a paper diary 
at 3 specific times daily for 3 weeks. When the diaries were 
returned, 90% of the expected data had been entered. How-
ever, a sensor hidden in the binding of the diaries demon-
strated that only 11% of these entries were made within the 
prescribed time frame. Furthermore, on 32% of study days 
the diaries were never even opened [12]. 
  In the current trial, subjects with mild to moderate persis-
tent asthma were approximately 90% compliant with their 
prescribed controller regimen over a 2-week period. This 
compliance would most likely have decreased had this been 
a longer trial. Using pharmacy claims data a 34% initial and 
25% 6-month compliance rate with ICS therapy has been 
reported for subjects not actively participating in a study 
protocol [22]. Although using a diary with an intrinsic elec-
tronic reminder system did not appear to improve compli-
ance compared to using a paper diary in the current evalua-
tion, this comparison depends upon paper diary entries that, 
as previously noted, may be neither timely nor accurately 
recorded. A previous evaluation comparing paper diary re-
sponses with actual ICS use, as determined by an electronic 
monitoring device, found that paper diary responses consis-
tently overstated actual ICS use [23]. Similar to the current 
evaluation, patients with asthma who were evaluating an-
other mobile phone-based system stated that the electronic 
reminder was helpful in remembering to take their medica-
tion and that they missed this reminder once participation in 
the trial ended [14]. Moreover, use of a mobile phone-based 
reminder system to improve compliance has been shown to 
be effective in other disorders [24]. This reminder activity 
warrants further investigation in the routine clinical man-
agement of patients with persistent asthma. 
  Finally, it is important to consider the limitations of the 
current evaluation. This was a small pilot study designed to 
assess acceptance and feasibility of using a mobile phone-
based system to electronically capture clinical information in 
subjects with mild to moderate persistent asthma. It was not 
designed to assess the accuracy of the data recorded in the 
diaries nor powered to detected significant differences be-
tween the two diary types in adherence or functional status 
outcomes. As such, it does not provide definitive answers. 
However, despite an estimated worldwide prevalence of 2.7 
billion mobile phones [17], few data exist on using this tech-
nology for electronic data collection, especially in patients 
with asthma. Previous evaluations of the use of mobile 
phone-based diary systems in patients with asthma by Anhoj 
and Cleland assessed 12 and 10 subjects, respectively [14, 
25]. The 12 subjects described in the current evaluation sub-
stantially augment this knowledge base, confirming the fea-
sibility and potential value of this technique and hopefully 
stimulating larger, more definitive randomized controlled 
clinical trials. Current data on subject acceptance of elec-
tronic data capture devices is also limited and contradictory. 
For example, in one crossover evaluation, 85% of subjects 
preferred a traditional paper diary over an interactive voice 
response system [15] whereas in another, 59% of subjects 
preferred a handheld computer system over a traditional pa-
per diary [21]. In the current evaluation, 58% of subjects 
preferred the mobile phone-based diary, lending support to 
the concept that subjects will accept and ultimately may pre-
fer to use electronic data capture devices. 
CONCLUSIONS 
  In this pilot evaluation, the VOCEL
® Mobile Diary was 
considered to be easy to use and was preferred by slightly 
Table 2.  Individual Subject Data 
 
Subject  Diary  
Preference 
Missing Data  
Points (Total) 
Reported 
Study  
Medication 
 Doses Taken  
(total) 
Reported 
 Rescue  
Medication 
 Doses Taken  
(total) 
Daytime  
Symptom 
Score 
 (mean) 
Nighttime 
Symptom  
Score 
 (mean) 
Nighttime 
Asthma  
Awakenings 
(total) 
Baseline 
Change in 
Percent FEV1 
    Paper Mobile Paper Mobile Paper Mobile Paper Mobile Paper Mobile Paper Mobile Paper Mobile 
1 P
*  3  4 27  26 0  4 0.0  0.2  1.1  1.1 0  0 2%  3% 
2 M
†  1  4 29  26  17 2 0.2  0.1  0.8  0.0 3  0 5%  2% 
3  M  3  2 27  28 2  2 0.2  0.1  0.1  0.0 0  0  -7%  -4% 
4  M  1  3 29  27 6  0 0.2  0.3  0.6  0.2 0  0  -2%  -4% 
5  M  2  4 28  26 1  0 0.0  0.0  0.1  0.0 0  0 1%  1% 
6  P  3  3 27  27 6  5 0.4  0.3  0.1  0.1 0  1 0%  6% 
7  P  3  9 23  20  18 11  0.9  0.5  1.4  0.8 1  2  -2%  -2% 
8  P  2  9 28  21 1  0 0.5  0.5  1.4  0.6 0  0  -9%  -7% 
9  P  2  5 28  25  10 18  0.1  0.3  0.4  0.4 1  0  -1%  1% 
10  M  6  8 24  22 3  3 0.0  0.0  0.1  0.3 0  0  -1%  1% 
11  M  4  5 26  25 6  8 0.2  0.3  0.2  0.5 0  0 0%  0% 
12  M  3  9 27  21  18 0 0.8  0.0  0.8  0.5 0  0  -10%  2% 
*P: preferred paper diary; 
†M: preferred mobile diary. 78    The Open Respiratory Medicine Journal, 2008, Volume 2  Meltzer et al. 
more subjects than the paper diary. Despite this, there were 
more missing data entries when recording with the mobile 
diary, most likely related to the strictly enforced time periods 
for these entries. Whether the additional entries in the paper 
diary are meaningful however, cannot be determined since 
there were no objective measures of either the time or the 
accuracy of these entries. Nonetheless, the apparent discrep-
ancy between diary reports of treatment compliance and 
asthma symptoms, need for rescue medication, and pulmo-
nary function tests suggests that these additional entries may 
not be completely reliable. 
  The ciclesonide MDI was safe, effective, and easy to use. 
Large, randomized, controlled clinical trials are warranted to 
confirm these findings and further evaluate the effect of di-
ary type on recorded responses. 
ABBREVIATIONS 
FEV1  =  Forced Expiratory Volume in 1 second 
GLM  =  General Linear Models 
HFA =  Hydrofluoroalkane 
ICS =  Inhaled  corticosteroid 
MDI =  Metered  dose  inhaler 
PEFR  =  Peak expiratory flow rate 
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